reimbursement zulresso based talks company insurance companies significant commercial challenge jonas adds helping hospitals prepare train staff administer drug treatment work women postpartum depression clearly major step hospital treatment probably appropriate women moderate severe symptoms struggling function home not able good care children said puryear certainly appropriate women severe symptoms cost benefit analysis paul matteis biotech analyst stifel forecasts zulresso generating $ 270 million u.s. sales 2023 given requirements hospital treatment matteis assumes drug use limited women severe postpartum depression initially sage current market value approaches $ 8 billion means investors expected zulresso approval accounted revenue valuation models investment case